Shixiang Wang
Research Subjects
Shixiang Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Han Li
Department of Nephrology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
12 shared publications Han Li
6 shared publications- Xiangxue Lu
Department of Blood Purification
6 shared publications - Jialing Zhang
Department of Blood Purification, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China,
2 shared publications - Jian Lu
Department of Nephrology, China-Japan Friendship Hospital, Beijing, China
2 shared publications - Jianan Feng
Department of Blood Purification, Beijing Chao‐Yang Hospital Capital Medical University Beijing China
2 shared publications
Latest Publications
- 12 May 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (11) , 2474-2484
Interaction effect of psoriasis and chronic kidney disease on the risk of all-cause mortality: a prospective cohort study of NHANES data
The association between psoriasis and chronic kidney disease (CKD) with mortality remains unclear. This study aimed to examine the combined impact of psoriasis and CKD on mortality in a representative sample of US adults. The data for this analysis came from 13 208 participants of the National Health and Nutrition Examination Survey conducted between 2003–2006 and 2009–2014. Psoriasis was determined through self-reported questionnaire data, while CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or urinary albumin to creatinine ratio (UACR) ≥ 30 mg/g. A four-level variable was created using the information on psoriasis and CKD, and survival probability was estimated using the Kaplan-Meier method. The survival analysis was conducted using weighted Cox proportional hazards regression models. In a 9.83-year average follow-up period, 539 deaths occurred, with a prevalence of psoriasis in CKD at 2.94% and an all-cause mortality rate of 33.30%. In the multivariable analyses, individuals with both psoriasis and CKD had 5.38 hazard ratios (HRs) [95% CI, 2.43–11.91] of all-cause mortality compared to those with neither psoriasis nor CKD. Participants with both psoriasis and low eGFR had an HRs of 6.40 [95% CI, 2.01–20.42], while those with both psoriasis and albuminuria had an HRs of 5.30 [95% CI, 2.24–12.52]. A significant interaction between psoriasis and CKD on all-cause mortality was found in the fully adjusted model (P = 0.026), and a significant synergistic effect between psoriasis and albuminuria was discovered (P = 0.002). However, the interaction effects between psoriasis and low eGFR on all-cause mortality were only observed in the unadjusted model (P = 0.036). Screening for psoriasis in individuals at risk for developing CKD may help in risk stratification for all-cause mortality related to psoriasis. The assessment of UACR may be useful in identifying psoriasis at increased risk for all-cause mortality.
- 12 May 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (11) , 2474-2484
Interaction effect of psoriasis and chronic kidney disease on the risk of all-cause mortality: a prospective cohort study of NHANES data
The association between psoriasis and chronic kidney disease (CKD) with mortality remains unclear. This study aimed to examine the combined impact of psoriasis and CKD on mortality in a representative sample of US adults. The data for this analysis came from 13 208 participants of the National Health and Nutrition Examination Survey conducted between 2003–2006 and 2009–2014. Psoriasis was determined through self-reported questionnaire data, while CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or urinary albumin to creatinine ratio (UACR) ≥ 30 mg/g. A four-level variable was created using the information on psoriasis and CKD, and survival probability was estimated using the Kaplan-Meier method. The survival analysis was conducted using weighted Cox proportional hazards regression models. In a 9.83-year average follow-up period, 539 deaths occurred, with a prevalence of psoriasis in CKD at 2.94% and an all-cause mortality rate of 33.30%. In the multivariable analyses, individuals with both psoriasis and CKD had 5.38 hazard ratios (HRs) [95% CI, 2.43–11.91] of all-cause mortality compared to those with neither psoriasis nor CKD. Participants with both psoriasis and low eGFR had an HRs of 6.40 [95% CI, 2.01–20.42], while those with both psoriasis and albuminuria had an HRs of 5.30 [95% CI, 2.24–12.52]. A significant interaction between psoriasis and CKD on all-cause mortality was found in the fully adjusted model (P = 0.026), and a significant synergistic effect between psoriasis and albuminuria was discovered (P = 0.002). However, the interaction effects between psoriasis and low eGFR on all-cause mortality were only observed in the unadjusted model (P = 0.036). Screening for psoriasis in individuals at risk for developing CKD may help in risk stratification for all-cause mortality related to psoriasis. The assessment of UACR may be useful in identifying psoriasis at increased risk for all-cause mortality.
- 13 November 2022
- Published by Wiley in Seminars in Dialysis
- Vol. 36 (3) , 247-254
High serum β2‐microglobulin is a significant predictor of mortality in maintenance hemodialysis patients
Background: Beta2‐microglobulin, a novel marker of kidney function, predicts kidney failure and mortality in the general population. However, few studies have evaluated the association of serum β2‐MG level with clinical outcome in maintenance hemodialysis (MHD) patients.Methods: This prospective cohort study enrolled 303 MHD patients to investigate the factors related to β2‐MG and its relationship to mortality in MHD patients. Multivariate linear regression analysis was used to examine the factors related to β2‐MG level. Multivariable Cox regression was used to calculate the hazard ratios for β2‐MG on all‐cause and cardiovascular mortality.Results: The median value of serum β2‐MG was 44.6 mg/L (interquartile range 37.60–50.40 mg/L). During the follow‐up period of 24 months, there were 48 all‐cause deaths (23.0%), including 36 cardiovascular causes (75.0% of all deaths). Multiple linear regression showed that dialysis duration, serum creatinine, and alkaline phosphatase were independent predictors of serum β2‐MG level. Kaplan–Meier analysis revealed that mortality in MHD patients was significantly higher in low albumin patients with β2‐MG > 44.6 mg/L. Cox regression analysis showed that β2‐MG was a significant predictor of all‐cause mortality (HR = 1.122, 95% CI: 1.058–1.190, 𝑃 < 0.001) and cardiovascular mortality (HR = 1.145, 95%CI: 1.065–1.123, P < 0.001) in MHD patients with low albumin level after adjusting for confounding factors. However, our results showed that serum β2‐MG was not associated with mortality in MHD patients with normal albumin level.Conclusion: These results are supportive of the potential role of the serum β2‐MG level as a predictor of mortality in MHD patients with low albumin.
- 13 November 2022
- Published by Wiley in Seminars in Dialysis
- Vol. 36 (3) , 247-254
High serum β2‐microglobulin is a significant predictor of mortality in maintenance hemodialysis patients
Background: Beta2‐microglobulin, a novel marker of kidney function, predicts kidney failure and mortality in the general population. However, few studies have evaluated the association of serum β2‐MG level with clinical outcome in maintenance hemodialysis (MHD) patients.Methods: This prospective cohort study enrolled 303 MHD patients to investigate the factors related to β2‐MG and its relationship to mortality in MHD patients. Multivariate linear regression analysis was used to examine the factors related to β2‐MG level. Multivariable Cox regression was used to calculate the hazard ratios for β2‐MG on all‐cause and cardiovascular mortality.Results: The median value of serum β2‐MG was 44.6 mg/L (interquartile range 37.60–50.40 mg/L). During the follow‐up period of 24 months, there were 48 all‐cause deaths (23.0%), including 36 cardiovascular causes (75.0% of all deaths). Multiple linear regression showed that dialysis duration, serum creatinine, and alkaline phosphatase were independent predictors of serum β2‐MG level. Kaplan–Meier analysis revealed that mortality in MHD patients was significantly higher in low albumin patients with β2‐MG > 44.6 mg/L. Cox regression analysis showed that β2‐MG was a significant predictor of all‐cause mortality (HR = 1.122, 95% CI: 1.058–1.190, 𝑃 < 0.001) and cardiovascular mortality (HR = 1.145, 95%CI: 1.065–1.123, P < 0.001) in MHD patients with low albumin level after adjusting for confounding factors. However, our results showed that serum β2‐MG was not associated with mortality in MHD patients with normal albumin level.Conclusion: These results are supportive of the potential role of the serum β2‐MG level as a predictor of mortality in MHD patients with low albumin.
- Open Access
- 5 August 2022
- Published by Taylor & Francis in Renal Failure
- Vol. 44 (1) , 1290-1309
The roles of hydrogen sulfide in renal physiology and disease states
Hydrogen sulfide (H2S), an endogenous gaseous signaling transmitter, has gained recognition for its physiological effects. In this review, we aim to summarize and discuss existing studies about the roles of H2S in renal functions and renal disease as well as the underlying mechanisms. H2S is mainly produced by four pathways, and the kidneys are major H2S–producing organs. Previous studies have shown that H2S can impact multiple signaling pathways via sulfhydration. In renal physiology, H2S promotes kidney excretion, regulates renin release and increases ATP production as a sensor for oxygen. H2S is also involved in the development of kidney disease. H2S has been implicated in renal ischemia/reperfusion and cisplatin–and sepsis–induced kidney disease. In chronic kidney diseases, especially diabetic nephropathy, hypertensive nephropathy and obstructive kidney disease, H2S attenuates disease progression by regulating oxidative stress, inflammation and the renin–angiotensin–aldosterone system. Despite accumulating evidence from experimental studies suggesting the potential roles of H2S donors in the treatment of kidney disease, these results need further clinical translation. Therefore, expanding the understanding of H2S can not only promote our further understanding of renal physiology but also lay a foundation for transforming H2S into a target for specific kidney diseases.
- 5 August 2022
- Published by Taylor & Francis in Renal Failure
- Vol. 44 (1) , 1290-1309
Open AccessThe roles of hydrogen sulfide in renal physiology and disease states
Hydrogen sulfide (H2S), an endogenous gaseous signaling transmitter, has gained recognition for its physiological effects. In this review, we aim to summarize and discuss existing studies about the roles of H2S in renal functions and renal disease as well as the underlying mechanisms. H2S is mainly produced by four pathways, and the kidneys are major H2S–producing organs. Previous studies have shown that H2S can impact multiple signaling pathways via sulfhydration. In renal physiology, H2S promotes kidney excretion, regulates renin release and increases ATP production as a sensor for oxygen. H2S is also involved in the development of kidney disease. H2S has been implicated in renal ischemia/reperfusion and cisplatin–and sepsis–induced kidney disease. In chronic kidney diseases, especially diabetic nephropathy, hypertensive nephropathy and obstructive kidney disease, H2S attenuates disease progression by regulating oxidative stress, inflammation and the renin–angiotensin–aldosterone system. Despite accumulating evidence from experimental studies suggesting the potential roles of H2S donors in the treatment of kidney disease, these results need further clinical translation. Therefore, expanding the understanding of H2S can not only promote our further understanding of renal physiology but also lay a foundation for transforming H2S into a target for specific kidney diseases.
- 26 July 2022
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (6) , 1421-1429
The kidney reabsorption-related magnesium depletion score is associated with increased likelihood of abdominal aortic calcification among US adults
Kidney reabsorption has a vital role in magnesium homeostasis. This study aimed to determine the relationship between the kidney reabsorption-related magnesium depletion score (MDS) and abdominal aortic calcification (AAC). We obtained the data of 2640 individuals from the National Health and Nutrition Examination Survey (NHANES) database and analyzed the relationship between MDS and AAC scores. MDS is a scoring system developed to predict status of magnesium deficiency that fully considered the pathophysiological factors influencing the kidneys’ reabsorption capability. AAC was quantified by the Kauppila score system based on dual-energy X-ray absorptiometry. We performed stratified analysis and multiple equation regression analysis. R and EmpowerStats were used for data analysis. A total of 2640 participants were included with the mean AAC score of 1.47 ± 0.07. Participants in higher MDS tended to have higher AAC scores (MDS scored 0: 0.75 (0.56, 0.93), MDS scored 1: 1.02 (0.84, 1.21), MDS scored 2: 2.34 (1.80, 2.87), MDS scored 3: 3.19 (2.46, 3.92), MDS ≥ 4: 4.99 (3.49, 6.49)). Compared with those in the lowest MDS scored 0, the highest subgroup (MDS ≥ 4) was associated with a higher AAC score (β = 4.24, 95% CI: 2.78–5.70, p < 0.001), and the association was not altered (β = 1.81, 95% CI: 0.54–3.09, p = 0.002) after adjusting for numerous covariates. Subgroup analyses showed that stronger associations between MDS and AAC score were detected in adults with lower levels of magnesium intake and older (all p for interaction < 0.05). The MDS is a promising tool for identifying individuals with magnesium deficiency status who may benefit from dietary magnesium supplementation to reduce the risks of AAC.
- 26 July 2022
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (6) , 1421-1429
The kidney reabsorption-related magnesium depletion score is associated with increased likelihood of abdominal aortic calcification among US adults
Kidney reabsorption has a vital role in magnesium homeostasis. This study aimed to determine the relationship between the kidney reabsorption-related magnesium depletion score (MDS) and abdominal aortic calcification (AAC). We obtained the data of 2640 individuals from the National Health and Nutrition Examination Survey (NHANES) database and analyzed the relationship between MDS and AAC scores. MDS is a scoring system developed to predict status of magnesium deficiency that fully considered the pathophysiological factors influencing the kidneys’ reabsorption capability. AAC was quantified by the Kauppila score system based on dual-energy X-ray absorptiometry. We performed stratified analysis and multiple equation regression analysis. R and EmpowerStats were used for data analysis. A total of 2640 participants were included with the mean AAC score of 1.47 ± 0.07. Participants in higher MDS tended to have higher AAC scores (MDS scored 0: 0.75 (0.56, 0.93), MDS scored 1: 1.02 (0.84, 1.21), MDS scored 2: 2.34 (1.80, 2.87), MDS scored 3: 3.19 (2.46, 3.92), MDS ≥ 4: 4.99 (3.49, 6.49)). Compared with those in the lowest MDS scored 0, the highest subgroup (MDS ≥ 4) was associated with a higher AAC score (β = 4.24, 95% CI: 2.78–5.70, p < 0.001), and the association was not altered (β = 1.81, 95% CI: 0.54–3.09, p = 0.002) after adjusting for numerous covariates. Subgroup analyses showed that stronger associations between MDS and AAC score were detected in adults with lower levels of magnesium intake and older (all p for interaction < 0.05). The MDS is a promising tool for identifying individuals with magnesium deficiency status who may benefit from dietary magnesium supplementation to reduce the risks of AAC.
- Open Access
- 3 May 2022
- Published by Springer Nature in BMC Psychiatry
- Vol. 22 (1) , 1-8
High neutrophil-to-lymphocyte ratio is a significant predictor of depressive symptoms in maintenance hemodialysis patients: a cross-sectional study
Background: Depression is one of the most important psychiatric disorders in chronic kidney disease patients who undergo maintenance hemodialysis (MHD). Previous studies have shown that low-grade inflammation is involved in the progression of depressive symptoms. The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory marker that is inexpensive and easy to measure. However, the association between NLR and depression symptoms in MHD patients has not been examined. Methods: In this single-center, cross-sectional study, we included 160 patients undergoing MHD. The Patient Health Questionnaire-9 (PHQ-9) was used to assess depressive symptoms. NLR was calculated as the ratio of neutrophils to lymphocytes. Multinomial logistic regression and multivariate linear regression analyses were used to examine the association between NLR and depressive symptoms in MHD patients. Results: Depressive symptoms were detected in 36.7% of the 160 MHD patients. Multinomial logistic regression showed that NLR was a significant predictor of mild (odds ratio [OR]: 1.383, 95% confidence interval [CI]: 1.015–1.884, p = 0.04) and moderate/moderately severe depressive symptoms (OR: 1.441, 95% CI: 1.017–2.042, p = 0.04) in MHD patients, adjusted for age, sex, Kt/V, dialysis duration, history of kidney transplantation, history of hypertension, and Charlson comorbidity index score. In addition, multivariate linear regression analysis showed that NLR was an independent influencing factor for PHQ-9 score in MHD patients, after adjusting for confounding factors. Conclusions: These findings suggest that NLR can be used as a biomarker for predicting depressive symptoms in MHD patients.
- 3 May 2022
- Published by Springer Nature in BMC Psychiatry
- Vol. 22 (1) , 1-8
Open AccessHigh neutrophil-to-lymphocyte ratio is a significant predictor of depressive symptoms in maintenance hemodialysis patients: a cross-sectional study
Background: Depression is one of the most important psychiatric disorders in chronic kidney disease patients who undergo maintenance hemodialysis (MHD). Previous studies have shown that low-grade inflammation is involved in the progression of depressive symptoms. The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory marker that is inexpensive and easy to measure. However, the association between NLR and depression symptoms in MHD patients has not been examined. Methods: In this single-center, cross-sectional study, we included 160 patients undergoing MHD. The Patient Health Questionnaire-9 (PHQ-9) was used to assess depressive symptoms. NLR was calculated as the ratio of neutrophils to lymphocytes. Multinomial logistic regression and multivariate linear regression analyses were used to examine the association between NLR and depressive symptoms in MHD patients. Results: Depressive symptoms were detected in 36.7% of the 160 MHD patients. Multinomial logistic regression showed that NLR was a significant predictor of mild (odds ratio [OR]: 1.383, 95% confidence interval [CI]: 1.015–1.884, p = 0.04) and moderate/moderately severe depressive symptoms (OR: 1.441, 95% CI: 1.017–2.042, p = 0.04) in MHD patients, adjusted for age, sex, Kt/V, dialysis duration, history of kidney transplantation, history of hypertension, and Charlson comorbidity index score. In addition, multivariate linear regression analysis showed that NLR was an independent influencing factor for PHQ-9 score in MHD patients, after adjusting for confounding factors. Conclusions: These findings suggest that NLR can be used as a biomarker for predicting depressive symptoms in MHD patients.
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 2413176
Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta‐Analysis of Randomized Controlled Trials including 6,518 Patients
Background. Roxadustat is a newly listed oral hypoxia‐inducible factor‐proline enhancing enzyme inhibitor (HIF‐PHI) in recent years. There have been some studies that have proved the efficacy of roxadustat on the treatment of renal anemia in patients with chronic kidney disease (CKD), but there are still different conclusions on its safety. Methods. PubMed, Embase, Cochrane, and ClinicalTrials were searched for randomized controlled trials (RCTs) that assess efficacy and safety of roxadustat treatment for anemia in CKD patients. The Cochrane Literature Quality Evaluation Scale was used to evaluate the quality of included literature. We choose fixed‐effects model or random effects model for data processing based on heterogeneity. It was considered statistically significant when p value Results. A total of 842 articles were retrieved, and 16 trials in the 15 articles were finally included. Roxadustat treatment significantly increased Hb levels. Iron (SMD 1.43, 95% CI 0.31 to 2.55), total iron‐binding capacity (SMD 2.06, 95% CI 0.91 to 3.22), ferritin (WMD 21.33, 95% CI 3.04 to 39.62), transferrin saturation (SMD 4.17, 95% CI 3.90 to 4.45), and LDL‐cholesterol (SMD ‐0.64, 95% CI ‐0.73 to ‐0.55) showed statistical significance in dialysis‐dependent (DD) study. And hepcidin (SMD ‐1.56, 95% CI ‐2.63 to ‐0.50), transferrin (SMD 1.80, 95% CI 1.53 to 2.06), total iron‐binding capacity (SMD 1.62, 95% CI 1.39 to 1.86), total cholesterol (SMD ‐0.88, 95% CI ‐1.68 to ‐0.09), ferritin (WMD ‐52.68, 95% CI ‐62.68 to ‐42.67), transferrin saturation (SMD ‐5.57, 95% CI ‐7.47 to ‐3.68), and LDL‐cholesterol (SMD ‐0.85, 95% CI ‐1.37 to ‐0.34) showed statistical significance in not dialysis‐dependent (NDD) study. In terms of safety, roxadustat treatment did not increase risk of total adverse events either in dialysis‐dependent or not dialysis‐dependent patients. Conclusion. Roxadustat can effectively improve anemia in patients with chronic kidney disease. There was no significant difference in total adverse events compared with the control group.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 2413176
Open AccessEfficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta‐Analysis of Randomized Controlled Trials including 6,518 Patients
Background. Roxadustat is a newly listed oral hypoxia‐inducible factor‐proline enhancing enzyme inhibitor (HIF‐PHI) in recent years. There have been some studies that have proved the efficacy of roxadustat on the treatment of renal anemia in patients with chronic kidney disease (CKD), but there are still different conclusions on its safety. Methods. PubMed, Embase, Cochrane, and ClinicalTrials were searched for randomized controlled trials (RCTs) that assess efficacy and safety of roxadustat treatment for anemia in CKD patients. The Cochrane Literature Quality Evaluation Scale was used to evaluate the quality of included literature. We choose fixed‐effects model or random effects model for data processing based on heterogeneity. It was considered statistically significant when p value Results. A total of 842 articles were retrieved, and 16 trials in the 15 articles were finally included. Roxadustat treatment significantly increased Hb levels. Iron (SMD 1.43, 95% CI 0.31 to 2.55), total iron‐binding capacity (SMD 2.06, 95% CI 0.91 to 3.22), ferritin (WMD 21.33, 95% CI 3.04 to 39.62), transferrin saturation (SMD 4.17, 95% CI 3.90 to 4.45), and LDL‐cholesterol (SMD ‐0.64, 95% CI ‐0.73 to ‐0.55) showed statistical significance in dialysis‐dependent (DD) study. And hepcidin (SMD ‐1.56, 95% CI ‐2.63 to ‐0.50), transferrin (SMD 1.80, 95% CI 1.53 to 2.06), total iron‐binding capacity (SMD 1.62, 95% CI 1.39 to 1.86), total cholesterol (SMD ‐0.88, 95% CI ‐1.68 to ‐0.09), ferritin (WMD ‐52.68, 95% CI ‐62.68 to ‐42.67), transferrin saturation (SMD ‐5.57, 95% CI ‐7.47 to ‐3.68), and LDL‐cholesterol (SMD ‐0.85, 95% CI ‐1.37 to ‐0.34) showed statistical significance in not dialysis‐dependent (NDD) study. In terms of safety, roxadustat treatment did not increase risk of total adverse events either in dialysis‐dependent or not dialysis‐dependent patients. Conclusion. Roxadustat can effectively improve anemia in patients with chronic kidney disease. There was no significant difference in total adverse events compared with the control group.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta‐Analysis
Introduction. The present meta‐analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria. Method. We systematically searched PubMed and Embase for studies that compared HCQ and other treatments to reduce proteinuria in patients with IgA nephropathy up to June 2021. Mean ± SD of percentage change and level of proteinuria was calculated. Results. A total of 5 studies with 587 participants were included. IgA nephropathy patients who received HCQ were at a lower level of mean proteinuria at 6 months. However, there was no statistical difference between HCQ and control group considering percentage reduction in proteinuria. The long‐term therapeutic effect of HCQ might be inferior to HCQ and renin‐angiotensin‐aldosterone system inhibition. Conclusion. HCQ might play a role in the reduction of proteinuria in IgA nephropathy patients. The addition of HCQ to other immunosuppressive agents should be clarified further.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessEffects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta‐Analysis
Introduction. The present meta‐analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria. Method. We systematically searched PubMed and Embase for studies that compared HCQ and other treatments to reduce proteinuria in patients with IgA nephropathy up to June 2021. Mean ± SD of percentage change and level of proteinuria was calculated. Results. A total of 5 studies with 587 participants were included. IgA nephropathy patients who received HCQ were at a lower level of mean proteinuria at 6 months. However, there was no statistical difference between HCQ and control group considering percentage reduction in proteinuria. The long‐term therapeutic effect of HCQ might be inferior to HCQ and renin‐angiotensin‐aldosterone system inhibition. Conclusion. HCQ might play a role in the reduction of proteinuria in IgA nephropathy patients. The addition of HCQ to other immunosuppressive agents should be clarified further.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
High Neutrophil‐to‐Lymphocyte Ratio and Platelet‐to‐Lymphocyte Ratio Are Associated with Poor Survival in Patients with Hemodialysis
Background. The neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are markers for systemic inflammation condition. Although NLR has emerged as a risk factor for poor survival in end‐stage renal disease (ESRD) patients, the relationship between PLR and mortality is still unknown. We aimed to explore the interaction of NLR and PLR in predicting mortality in hemodialysis (HD) patients. Method. We enrolled 360 HD patients for a 71‐month follow‐up. The endpoint was all‐cause and cardiovascular (CV) mortality. Pearson correlation analysis was conducted to evaluate the relationship between factors and NLR or PLR. Kaplan‐Meier curves and Cox proportional analysis were used to assess the prognostic value of NLR and PLR. Results. NLR was positively correlated with neutrophil and negatively correlated with lymphocyte, hemoglobin, and serum albumin. PLR was positively correlated with neutrophil and platelet and negatively correlated with lymphocyte and hemoglobin. In multivariate Cox regression, a higher NLR level was independently associated with all‐cause mortality (OR 2.011, 95% CI 1.082‐3.74, p = 0.027), while a higher PLR level might predict CV mortality (OR 2.768, 95% CI 1.147‐6.677, p = 0.023) in HD patients. Conclusion. NLR and PLR are cheap and reliable biomarkers for all‐cause and CV mortality to predict survival in HD patients.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessHigh Neutrophil‐to‐Lymphocyte Ratio and Platelet‐to‐Lymphocyte Ratio Are Associated with Poor Survival in Patients with Hemodialysis
Background. The neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are markers for systemic inflammation condition. Although NLR has emerged as a risk factor for poor survival in end‐stage renal disease (ESRD) patients, the relationship between PLR and mortality is still unknown. We aimed to explore the interaction of NLR and PLR in predicting mortality in hemodialysis (HD) patients. Method. We enrolled 360 HD patients for a 71‐month follow‐up. The endpoint was all‐cause and cardiovascular (CV) mortality. Pearson correlation analysis was conducted to evaluate the relationship between factors and NLR or PLR. Kaplan‐Meier curves and Cox proportional analysis were used to assess the prognostic value of NLR and PLR. Results. NLR was positively correlated with neutrophil and negatively correlated with lymphocyte, hemoglobin, and serum albumin. PLR was positively correlated with neutrophil and platelet and negatively correlated with lymphocyte and hemoglobin. In multivariate Cox regression, a higher NLR level was independently associated with all‐cause mortality (OR 2.011, 95% CI 1.082‐3.74, p = 0.027), while a higher PLR level might predict CV mortality (OR 2.768, 95% CI 1.147‐6.677, p = 0.023) in HD patients. Conclusion. NLR and PLR are cheap and reliable biomarkers for all‐cause and CV mortality to predict survival in HD patients.
- Open Access
- 4 December 2020
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-9
CSE/H2S system alleviates uremic accelerated atherosclerosis by regulating TGF-β/Smad3 pathway in 5/6 nephrectomy ApoE−/− mice
Background: Hydrogen sulfide (H2S) has been shown to inhibit the atherosclerosis development and progression. It is produced by cystathionine γ-lyase (CSE) in the cardiovascular system. In our previous study, it has been shown that CSE/H2S system plays a significant role in the changes of uremic accelerated atherosclerosis (UAAS), but the mechanism is not known clearly.Methods: In this study, we explored the antagonism of CSE/H2S system in UAAS and identified its possible signaling molecules in ApoE−/−mice with 5/6 nephrectomy and fed with atherogenic diet. Mice were divided into sham operation group (sham group), UAAS group, sodium hydrosulfide group (UAAS+NaHS group) and propargylglycine group (UAAS+PPG group). Serum creatinine, urea nitrogen, lipid levels and lesion size of atherosclerotic plaque in the aortic roots were analyzed. Meanwhile, the expression of CSE, TGF-β and phosphorylation of Smad3 were detected.Results: Compared with sham group, the aortic root of ApoE−/−mice in the UAAS group developed early atherosclerosis, the levels of total cholesterol, triglyceride, low-density lipoprotein-cholesterol, serum creatinine and urea nitrogen were also higher than that in the sham group. NaHS administration can inhibit the development of atherosclerosis, but PPG administration can accelerate the atherosclerosis development. Meanwhile, the protein expression levels of CSE and TGF-β and phosphorylation of Smad3 significantly decreased in the UAAS mice. Treatment of UAAS mice with NaHS inhibited TGF-β protein expression and Smad3 phosphorylation decrease, but PPG treatment had the opposite effect.Conclusions: The CSE/H2S system is of great importance for treating atherosclerosis in patients with chronic kidney disease, and it may protect the vascular from atherosclerosis through the TGF-β/Smad pathway.
- 4 December 2020
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-9
Open AccessCSE/H2S system alleviates uremic accelerated atherosclerosis by regulating TGF-β/Smad3 pathway in 5/6 nephrectomy ApoE−/− mice
Background: Hydrogen sulfide (H2S) has been shown to inhibit the atherosclerosis development and progression. It is produced by cystathionine γ-lyase (CSE) in the cardiovascular system. In our previous study, it has been shown that CSE/H2S system plays a significant role in the changes of uremic accelerated atherosclerosis (UAAS), but the mechanism is not known clearly.Methods: In this study, we explored the antagonism of CSE/H2S system in UAAS and identified its possible signaling molecules in ApoE−/−mice with 5/6 nephrectomy and fed with atherogenic diet. Mice were divided into sham operation group (sham group), UAAS group, sodium hydrosulfide group (UAAS+NaHS group) and propargylglycine group (UAAS+PPG group). Serum creatinine, urea nitrogen, lipid levels and lesion size of atherosclerotic plaque in the aortic roots were analyzed. Meanwhile, the expression of CSE, TGF-β and phosphorylation of Smad3 were detected.Results: Compared with sham group, the aortic root of ApoE−/−mice in the UAAS group developed early atherosclerosis, the levels of total cholesterol, triglyceride, low-density lipoprotein-cholesterol, serum creatinine and urea nitrogen were also higher than that in the sham group. NaHS administration can inhibit the development of atherosclerosis, but PPG administration can accelerate the atherosclerosis development. Meanwhile, the protein expression levels of CSE and TGF-β and phosphorylation of Smad3 significantly decreased in the UAAS mice. Treatment of UAAS mice with NaHS inhibited TGF-β protein expression and Smad3 phosphorylation decrease, but PPG treatment had the opposite effect.Conclusions: The CSE/H2S system is of great importance for treating atherosclerosis in patients with chronic kidney disease, and it may protect the vascular from atherosclerosis through the TGF-β/Smad pathway.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Renal Failure
- Vol. 42 (1) , 1076-1082
Hepatitis C virus and carpal tunnel syndrome in hemodialysis patients: a single center cross-sectional study
Carpal tunnel syndrome (CTS) is a common complication in maintenance hemodialysis (MHD) patients and leads to disabilities and increased risk of mortality. Hepatitis C virus (HCV) infection is asso...
- 1 January 2020
- Published by Taylor & Francis in Renal Failure
- Vol. 42 (1) , 1076-1082
Open AccessHepatitis C virus and carpal tunnel syndrome in hemodialysis patients: a single center cross-sectional study
Carpal tunnel syndrome (CTS) is a common complication in maintenance hemodialysis (MHD) patients and leads to disabilities and increased risk of mortality. Hepatitis C virus (HCV) infection is asso...